[1] A. Furlan, V. Dyachuk, M.E. Kastriti, et al., Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla, Science 357 (2017), eaal3753.
[2] C. Delloye-Bourgeois, V. Castellani, Hijacking of embryonic programs by neural crest-derived neuroblastoma: from physiological migration to metastatic dissemination, Front. Mol. Neurosci. 12 (2019) 52.
[3] M. Ponzoni, T. Bachetti, M.V. Corrias, et al., Recent advances in the developmental origin of neuroblastoma: an overview, J. Exp. Clin. Cancer Res. 41 (2022) 92.
[4] G.M. Brodeur, Neuroblastoma: biological insights into a clinical enigma, Nat. Rev. Cancer 3 (2003) 203–216.
[5] J.M. Maris, M.D. Hogarty, R. Bagatell, S.L. Cohn, Neuroblastoma, Lancet 369 (2007) 2106–2120.
[6] N.R. Pinto, M.A. Applebaum, S.L. Volchenboum, et al., Advances in risk classification and treatment strategies for neuroblastoma, J. Clin. Oncol. 33 (2015) 3008–3017.
[7] V.P. Tolbert, K.K. Matthay, Neuroblastoma: clinical and biological approach to risk stratification and treatment, Cell Tissue Res. 372 (2018) 195–209.
[8] J.M. Maris, Recent advances in neuroblastoma, N. Engl. J. Med. 362 (2010) 2202–2211.
[9] S. Uemura, T. Ishida, K.K.M. Thwin, et al., Dynamics of minimal residual disease in neuroblastoma patients, Front. Oncol. 9 (2019) 455.
[10] D.A. Morgenstern, U. Potschger, L. Moreno, et al., Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study, Pediatr. Blood Cancer 65 (2018), e27363.
[11] W.B. London, V. Castel, T. Monclair, et al., Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project, J. Clin. Oncol. 29 (2011) 3286–3292.
[12] K. Beiske, P.F. Ambros, S.A. Burchill, I.Y. Cheung, K. Swerts, Detecting minimal residual disease in neuroblastoma patients-the present state of the art, Cancer Lett. 228 (2005) 229–240.
[13] S.C. Brownhill, S.A. Burchill, PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - focus on neuroblastoma, Pract Lab Med 7 (2017) 41–44.
[14] J. Stutterheim, L. Zappeij-Kannegieter, R. Versteeg, H.N. Caron, C.E. van der Schoot, G.A. Tytgat, The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma, Eur. J. Cancer 47 (2011) 1193–1202.
[15] V.F. Viprey, W.M. Gregory, M.V. Corrias, et al., Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study, J. Clin. Oncol. 32 (2014) 1074–1083.
[16] N.K. Cheung, I. Ostrovnaya, D. Kuk, I.Y. Cheung, Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy, J. Clin. Oncol. 33 (2015) 755–763.
[17] A. Marachelian, J.G. Villablanca, C.W. Liu, et al., Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis, Clin. Cancer Res. 23 (2017) 5374–5383.
[18] K.K.M. Thwin, T. Ishida, S. Uemura, et al., Level of seven neuroblastoma-associated mRNAs detected by droplet digital PCR is associated with tumor relapse/regrowth of high-risk neuroblastoma patients, J. Mol. Diagn. 22 (2020) 236–246.
[19] K.S. Lin, S. Uemura, K.K.M. Thwin, et al., Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood, Transl. Oncol 14 (2021), 101019.
[20] S.A. Burchill, K. Beiske, H. Shimada, et al., Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group, Cancer 123 (2017) 1095–1105.
[21] S.G. Kreissman, R.C. Seeger, K.K. Matthay, et al., Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial, Lancet Oncol. 14 (2013) 999–1008.
[22] S.A. Burchill, S.E. Kinsey, S. Picton, et al., Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma, Med. Pediatr. Oncol. 36 (2001) 213–219.
[23] M.V. Corrias, R. Haupt, B. Carlini, et al., Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients, Clin. Cancer Res. 12 (2006) 5680–5685.
[24] S. Avigad, G. Feinberg-Gorenshtein, D. Luria, et al., Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients, J. Pediatr. Hematol. Oncol. 31 (2009) 22–26.
[25] F. Chambon, A. Tchirkov, B. Pereira, E. Rochette, F. Demeocq, J. Kanold, Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma, Pediatr. Blood Cancer 60 (2013) E109–112.
[26] E.M. van Wezel, J. Stutterheim, F. Vree, et al., Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma, Pediatr. Blood Cancer 62 (2015) 1368–1373.
[27] E.M. van Wezel, L.M.J. van Zogchel, J. van Wijk, et al., Mesenchymal neuroblastoma cells are undetected by current mRNA marker panels: the development of a specific neuroblastoma mesenchymal minimal residual disease panel, JCO Prec. Oncol. 3 (2019) 1–11.
[28] W.H. Liang, S.M. Federico, W.B. London, et al., Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future, JCO Clin. Cancer Inform 4 (2020) 895–905.
[29] S.L. Cohn, A.D.J. Pearson, W.B. London, et al., The international neuroblastoma risk group (INRG) classification system: an INRG task force report, J. Clin. Oncol. 27 (2009) 289–297.
[30] T. Hishiki, K. Matsumoto, M. Ohira, et al., Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG), Int. J. Clin. Oncol. 23 (2018) 965–973.
[31] S. Uemura, K.S. Lin, K.K. Mon Thwin, et al., Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients, Mol Clin Oncol 15 (2021) 137.
[32] S.A. Bustin, V. Benes, J.A. Garson, et al., The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, Clin. Chem. 55 (2009) 611–622.
[33] J.F. Huggett, C.A. Foy, V. Benes, et al., The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments, Clin. Chem. 59 (2013) 892–902.
[34] A.K. Akobeng, Understanding diagnostic tests 3: receiver operating characteristic curves, Acta Paediatr. 96 (2007) 644–647.
[35] Y. Kanda, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marr. Transp. 48 (2013) 452–458.
[36] V. Boeva, C. Louis-Brennetot, A. Peltier, et al., Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries, Nat. Genet. 49 (2017) 1408–1413.
[37] T. van Groningen, J. Koster, L.J. Valentijn, et al., Neuroblastoma is composed of two super-enhancer-associated differentiation states, Nat. Genet. 49 (2017) 1261–1266.
[38] M. Gautier, C. Thirant, O. Delattre, I. Janoueix-Lerosey, Plasticity in neuroblastoma cell identity defines a noradrenergic-to-mesenchymal transition (NMT), Cancers 13 (2021) 2904.
[39] S.A. Burchill, P.J. Selby, Molecular detection of low-level disease in patients with cancer, J. Pathol. 190 (2000) 6–14.
論文の公開元へ
